2 Abstract Background: Five years of tamoxifen reduces breast cancer risk by nearly 50% but is
INTRODUCTION
Estrogen receptor-alpha (ESR1) signaling is a key driver of breast carcinogenesis; consequently, agents which modulate ESR1 activity or deplete its ligand reduce breast cancer incidence. However, estrogen signaling plays a critical role in diverse biological processes accounting for the frequent adverse events that occur when this pathway is pharmacologically perturbed. Tamoxifen is a selective estrogen receptor modifier (SERM) that has been shown to reduce breast cancer incidence by nearly 50% in increased risk women (1) , but it also increases the risk for endometrial cancer and venous thromboembolic events. Chemoprevention research has focused primarily on identifying SERMs with better safety profiles, but understanding critical molecular events occurring downstream of ESR1 may permit the development of paradigm-shifting chemoprevention approaches capable of specifically targeting benign breast tissue to reduce breast cancer incidence.
There is increasing interest in the role of insulin-like growth factor (IGF) signaling in breast carcinogenesis and progression. Tamoxifen has previously been shown to reduce circulating IGF-1(2),(3) and IGF-1 has been proposed as a surrogate endpoint biomarker for Phase II chemoprevention trials(4), (5) , (6) . It is unclear, however, whether systemic modulation of IGF-1 is simply a bystander effect or a key mediator of tamoxifen effects in benign breast tissue.
There is considerable published information concerning the effects of tamoxifen on breast cancer and breast cancer cell lines, but very little for benign breast tissue. carcinogenesis, may suggest targets for novel prevention approaches, and may provide biomarkers useful as surrogate endpoints in prevention trials.
MATERIALS AND METHODS

Study Design
A Phase II multi-institutional randomized, prospective, double blind placebocontrolled trial was conducted to identify biomarkers that are modulated by tamoxifen but not placebo in women at increased risk for breast cancer (ClinicalTrials.gov NCT00096369). This research was performed in accordance with an assurance filed with and approved by the U.S. Department of Health and Human Services. Institutional Review Board approval was obtained at each site and informed consent was documented in writing for each participant. Women > 35 years of age with a 5-year Gail risk > 1.67% or a personal history of lobular carcinoma in situ (LCIS) were eligible. Exclusion criteria included ever-use of SERMs, use of systemic steroid hormones (including oral contraceptives or hormone replacement therapy) within three months, personal history of invasive or in situ breast cancer, pregnancy or lactation within six months, a history of thromboembolic disease that would preclude the use of tamoxifen, the presence of breast implants, or a bleeding diathesis that would preclude needle sampling of the breast.
Eligible and consenting women were centrally randomized (Efron-type biased coin randomization) to tamoxifen or placebo. Stratification variables included 5 year Gail risk < or > 5%, history of high risk preneoplasia including atypical ductal hyperplasia, atypical lobular hyperplasia or LCIS, and menopausal status. Criteria for classifying a woman as postmenopausal included prior bilateral oophorectomy, amenorrhea for > 12
Cancer Research. months with an intact uterus and at least one ovary, or amenorrhea and FSH > 20 mIU/ml. Women not meeting any of these criteria were classified as premenopausal.
Blood and breast tissue samples were collected at baseline and after three months of tamoxifen or placebo.
The original study design called for enrollment of 130 women to provide 50 evaluable subjects in each treatment group while allowing for a 23% attrition rate prior to the second time point sampling. This sample size was judged sufficient to provide 80% power to recognize 17 -25% differences in modulation of selected biomarkers in tamoxifen subjects as compared to placebo subjects with two-tailed alpha set at 0.05. Antonio). Attrition prior to the second sampling was 5.5% (four subjects).
Biological Samples
Biological samples were collected by venipuncture, bilateral random periareolar fine needle aspiration (RP-FNA), and unilateral breast tissue core biopsy at baseline and after a median of 84 days of treatment with tamoxifen or placebo. For premenopausal women, the baseline and post-treatment samples were obtained on day 28 of the menstrual cycle +/-2 days. Late luteal phase sampling was specifically chosen to avoid measuring acute estrogenic effects while still capturing events (e.g. apoptosis) in a tissue remodeling phase(7). Blood was collected by venipuncture into Vacutainer CPT tubes (Becton Dickinson) which were immediately centrifuged to separate plasma and lymphocytes.
Aliquots were immediately frozen at -80 o C. Bilateral RP-FNA was performed as previously described (8), (9) . Direct smears were made for cytological assessment and material from each breast was pooled in PreserveCyt (Cytyk Health Corporation) for subsequent DNA extraction. Fourteen-gauge core needle samples were obtained from the palpably dense tissue in the upper outer quadrant of one breast for each patient. Two cores were immediately snap-frozen in liquid nitrogen for later RNA extraction, and the others were fixed in formalin for histological assessment and immunohistochemistry.
Post-treatment core biopsies were performed in the same breast sampled at baseline.
Treatment
Subjects were provided with a one month supply of identically labeled tamoxifen or placebo. The tamoxifen dose was 20 mg orally each day. Compliance was measured by pill counts every four weeks.
Biomarker Selection
The biomarker panel included markers known to be modulated by tamoxifen (e.g.
IGF-1)
, recently proposed markers of breast cancer risk (e.g. RP-FNA cytology(10), number of acini per lobule(11), (12) , and DNA methylation (8) , (9) 
Plasma Markers
To avoid repeated freezing and thawing, all of the assays for a given sample were usually run on the same day. Baseline and post-treatment samples for a given individual were always run on the same plate. Plasma markers included estradiol (RIA, DSL-39100, Diagnostic Systems Laboratories Inc.), albumin (QuantiChrom BCG Albumin Assay Kit, BioAssay Systems), sex hormone binding globulin (SHBG, ELISA, DSL-10-7400), prolactin (ELISA, DSL-10-4500), IGF-1 (ELISA, DSL-10-5600), IGF-2 (ELISA, DSL-10-2600), IGFBP-1 (ELISA, DSL-10-7800), and IGFBP-3 (ELISA, DSL-10-6600).
Free estradiol was calculated from total estradiol, albumin and SHBG as previously described (13) .
Tissue Core Markers
Histological assessment of hematoxyllin and eosin-stained slides was performed by a single breast pathologist (VS), specifically evaluating the characteristics of the epithelium: normal, non-proliferative fibrocystic change, or proliferative fibrocystic change. Specific histological patterns were recorded, including cystic changes, apocrine metaplasia, adenosis, sclerosing adenosis, papilloma/papillomatosis, epithelial hyperplasia (mild, moderate, or florid), atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), columnar cell change, or LCIS. Tumor suppressor gene methylation was measured by Quantitative Multiplex Methylation-specific PCR (QM-PCR) (15) . Markers evaluated included cyclin D2, APC, HIN-1, CST6, RASSF1A, and RAR-β2. The primers, probes, and performance characteristics of this assay have been described previously (16) .
CYP2D6 Genotypes
CYP2D6 genotyping was performed in the laboratory of Dr. David Flockhart on DNA extracted from peripheral blood mononuclear cells isolated from whole blood of the tamoxifen subjects using methods that have previously been described (17) . The observed alleles included *1, *2, *4, *5, *9, *11, *12, and *41. Patients with one or more *4 or *5 alleles were classified as poor metabolizers.
Gene Expression
RNA was extracted from 113 snap frozen breast tissue core samples (Qiazol and the RNeasy Micro Kit, Qiagen), amplified once, (TargetAmp Biotin-aRNA Amplification Kit, Epicentre Biotechnologies) and then hybridized to the Illumina whole genome 48k chip (Human-6 v2). An RNA Integrity Number (RIN) was measured for each sample using an Agilent 2100 Bioanalyzer. The RINs ranged from 6.6 to 9.1 with an average of 7.9. Core biopsy samples with few or no epithelial structures were excluded; consequently, the microarray analysis described in the results section is based on 70 arrays (35 two-time point pairs). Reasons for excluding arrays included < 5 lobules in The expression data is available at NCBI GEO GSE293338.
RNA was also extracted from microdissected lobules from 5 tamoxifen-treated subjects (2 premenopausal and 3 postmenopausal), amplified twice, and then hybridized to Illumina whole genome 48k chips (NCBI GEO GSE29338). Data from these doubly amplified samples did not meet the quality criteria established for the whole tissue cores and was judged unreliable for whole genome assessment of tamoxifen-modulated gene expression. Instead, these data were used to confirm the epithelial cell relevance of observations from the whole tissue cores. Mean Log2 ratios (post-treatment/baseline) > 1.5-fold up or down were considered significant in the microdissected lobules.
Reverse transcriptase PCR (RT-PCR) was used to confirm microarray observations for selected genes. cDNA was prepared from RNA extracted from snap frozen core samples using the SuperScript VILO cDNA Synthesis kit (Invitrogen). RT-PCR reactions were performed in Sybr premix Ex Taq II (TAKARA BIO, Inc.) using 5 ng of starting template on a Chromo4 thermocycler (BIO-RAD). The RT-PCR primer sequences are provided in Supplemental Table 3 . Normalized Relative Quantities (NRQ) were calculated according to the method of Hellesman (18) 
Data Analysis
For each plasma marker, the mean Log2 ratio (post-treatment/baseline) for tamoxifen subjects was compared with placebo subjects using two-tailed T-tests. For display purposes (Figure 1 analysis combined data from both pre-and postmenopausal women. Genes showing significant modulation in the tamoxifen subjects, based on Benjamin-Hockberg false discovery rate-corrected P-values < 0.05 (paired T-test), were retained (232 genes). To identify genes significantly modulated in the tamoxifen, but not the placebo subjects, mean post-treatment/baseline Log2 ratios and standard deviations were calculated for the tamoxifen (μT and SD_T) and the placebo (μP and SD_P) subjects for each gene according to the class prediction method of Slonim (19) . 50 genes were identified with (μT -μP)/(SD_T + SD_P) > 0.5. In a second analysis, pre-menopausal subjects (10 tamoxifen pairs and 8 placebo pairs) were analyzed separately from postmenopausal subjects (11 tamoxifen pairs and 8 placebo pairs). With the reduced samples sizes in this subgroup analysis, no significant Benjamin-Hockberg-corrected P-values were obtained.
Criteria for classifying a gene as modulated by tamoxifen but not placebo was relaxed to include, 1) mean fold change in tamoxifen subjects > 1.5 with P < 0.001, and 2) (μT - treatment. Four of these women (5.5%) withdrew from the study prior to the second sampling. One placebo subject was found to have a mammographically occult infiltrating lobular carcinoma on screening MRI obtained as part of her regular clinical management. Three tamoxifen subjects withdrew because of symptoms they attributed to the study medication. A total of 69 women completed all study-related activities including 37 in the tamoxifen group and 32 in the placebo group. Stratification was judged successful based on the similarity of the treatment groups for age, menopausal status, and breast cancer risk (Table 1) . Medication compliance, based on pill counts, was > 90% for all but two placebo subjects. Additional evidence for compliance is provided by the observation that 63% of the tamoxifen subjects reported hot flashes as compared to 33% of the placebo subjects (P = 0.024).
Blood Markers
Tamoxifen significantly increased total estradiol in both pre-and postmenopausal women, but this effect was most pronounced for premenopausal women (Figure 1 ).
Increases in total estradiol translated into increased free estradiol for premenopausal women, but the large increases in SHBG seen in postmenopausal women largely offset the modest increase in total estradiol. In general, tamoxifen reduced IGF-1 and increased IGF-2 and IGFBP1, but only marginally affected IGFBP3 (7% increase, P = 0.126).
Gene Expression Modulated by Tamoxifen but not Placebo
Cancer Research. 
The initial microarray analysis, which included samples from both premenopausal and postmenopausal women, identified 50 genes significantly modulated by tamoxifen but not placebo (Supplemental Table 1 ). Unsupervised hierarchical Pearson-centered clustering using a centroid linkage rule based on Log2 ratios (post-treatment/baseline) for these 50 genes clearly identified a highly related tamoxifen cluster largely distinct from the placebo-treated subjects (Figure 2A ). Twenty-one of these genes were significantly modulated in microdissected lobules from tamoxifen-treated subjects (marked with * in Supplemental Table 1) , and in each case the direction of modulation was identical to that observed in the whole breast cores. Known estrogen response genes such as ESR1, GREB1, and SERPINA3 were significantly downregulated; but, notably, the etsoncogene family transcription factors ETV4 and ETV5 were among the most significantly downregulated genes.
In the second analysis, pre-menopausal subjects were analyzed separately from postmenopausal subjects. This identified 26 genes significantly modulated by tamoxifen but not placebo in premenopausal women (Supplemental Table 2 ), but no genes met the criteria described in the Methods section for postmenopausal women (ESR1 was downregulated 1.94-fold, P = 0.005). Hierarchical cluster analysis based on the 26 genes identified in premenopausal women clearly identified a highly related premenopausal tamoxifen cluster largely distinct from the premenopausal placebo-treated subjects ( Figure 2B) . Fifteen of these genes were significantly modulated in microdissected lobules from tamoxifen-treated subjects (marked with * in Supplemental Table 2 ), and in each case the direction of modulation was identical to that observed in the whole breast cores. Known estrogen response genes such as ESR1 and SERPINA3 were significantly Tables 1 and 2 ). Tamoxifen downregulated the expression of each of these genes except CD200R1, TEK, and RAB35 which were upregulated. Pathway analysis based on these 69 genes identified ESR1 and the RABinteracting protein TBC1D9 as major interaction nodes, and identified estrogen receptor signaling and ceramide metabolism as key processes (Supplemental Figure 1) .
Gene expression array data were confirmed by RT-PCR for selected genes thought to be particularly relevant to the main effects of tamoxifen in benign breast tissue (Figure 3 ). In general, there was excellent correlation between microarray and RT-PCR expression values (Supplemental Table 4 ). As with the array data, significant modulation was generally only observed for premenopausal subjects. Among premenopausal subjects, tamoxifen, but not placebo, significantly downregulated the ets-oncogene transcription factors ETV4 and ETV5, as well as a gene thought to function as an ESR1 chaperone, DNAJC12. Of note, modulation of ETV4, ETV5, and DNAJC12 was entirely independent of tamoxifen-induced changes in plasma estradiol or IGFs but increasing plasma IGFBP3 was correlated with reduced expression of ETV4 (Spearman r = -0.616, P = 0.005). Baseline ETV4 expression was highly correlated with ETV5 expression (Spearman r = 0.707, P <0.0001) and treatment-associated changes in ETV4 
Breast Epithelial Proliferation
The median proliferative index for breast epithelial cells at baseline was 1.5% for premenopausal women and 0.6% for postmenopausal women. On average, three months of tamoxifen was associated with a 51% reduction in proliferation (P = 0.05) and placebo a 50% increase in proliferation (P = 0.15).
The volcano plot in Figure 5 heterozygotes as compared to the homozygous wild-type subjects (P = 0.47). Figure 5 shows that the CYP2D6 *4 or *5 heterozygotes are evenly distributed among subjects manifesting and not manifesting a significant anti-proliferative response to tamoxifen.
The effects of homozygous poor metabolizer genotypes are not known.
Apoptosis
Baseline mean apoptosis rate, as measured by TUNEL in breast tissue cores, was 4.9% for premenopausal subjects and 4.5% for postmenopausal subjects. ETV5 expression was modestly inversely correlated with apoptosis in baseline samples (Spearman r = -0.382, 95% CI -0.640 --0.045, P = 0.024). However, tamoxifen did not modulate apoptosis as measured by TUNEL at three months.
Estrogen Receptor
Though ESR1 measured by IHC was reduced a median of 27% with tamoxifen, and increased a median of 11% with placebo, this was not statistically significant (P = 0.058). However, tamoxifen was associated with a median reduction in ESR1 gene expression of 49% as measured by microarray (P <0.0001) but only an 8% reduction in placebo subjects (P = 0.447). This result was confirmed by RT-PCR which showed a median reduction of 49% for tamoxifen-treated subjects (P = 0.005) and a 4% decrease for placebo-treated subjects (P = 0.98). In breast cancer, ETV4 (20) and ETV5 (21) expression have been inversely correlated with ESR1 expression. We observed an inverse correlation between baseline ETV5 expression in benign breast tissue and ESR1 protein expression measured by IHC (Spearman r = -0.398, 95% CI = -0.652 --0.065, P = 0.018).
Breast Tissue Histology and Cytology
Lobular architecture, specifically the number of acini per lobule, has previously been linked to breast cancer risk (11), (12) . The mean acini per lobule ratio, assessed at 
RASSF1A methylation measured at baseline in RP-FNA samples (Spearman r = 0.442, 95% CI = 0.117 -0.681, P = 0.008). Tamoxifen did not modulate methylation of CCND2, HIN1, CST6, or RAR-β2, but the mean difference for the sum of APC and RASSF1A methylation fractions between post-treatment and baseline samples was +7.1% for placebo subjects and -3.5% for tamoxifen subjects (P = 0.021).
Other Markers
Tamoxifen did not modulate breast tissue EGFR expression as measured by IHC or plasma prolactin. The proportion of BCL2 3+ cases increased from 40.0% to 85.7% for premenopausal tamoxifen subjects (Fisher's exact test p = 0.029), and from 31.3% to 60.0% for premenopausal placebo subjects (p = 0.212), but BCL2 was not modulated in postmenopausal subjects.
DISCUSSION
Tamoxifen downregulates mRNA expression of ets-oncogene family members, ETV4 and ETV5, independent of changes in plasma estradiol, IGF1, IGF2, or IGFBP1 suggesting a direct transcriptional effect. ETV4 is a known estrogen response gene (22) .
ETV4 and ETV5 belong to the PEA3 subfamily of ets-oncogene family transcription factors. In rodent models, these transcription factors are essential for maintaining stem cell niches (23) , (24), (25) and regulating branching morphogenesis of epithelial structures (26) , (27) , During pubertal murine mammary gland development, and subsequent lobular expansion in early pregnancy, ETV4 and ETV5 maintain the self- 
through the stroma, and also regulate alveolar differentiation at the terminal end buds(28), (27) , (29) . The precise role of ETV4 and ETV5 in the human mammary gland is not known.
Known transcriptional targets of ETV4 and ETV5 include proteases (20) , (30), (31) , genes involved in epithelial stromal interaction, such as PTHLH (32) Tamoxifen also significantly modulated the expression of genes belonging to, or interacting with, Ras superfamily G proteins involved in intracellular vesicle trafficking (RAB3B, RAB38, RAB35, and SYTL2). These genes are not known to be regulated by ETV4 or ETV5. Of note, tamoxifen significantly upregulated TEK, a tyrosine kinase associated with angiogenesis(36) and poor prognosis breast cancer (37) , (38) , and also marginally upregulated PIM1, a serine/threonine protein kinase recognized as a protooncogene(39), (40) . Tamoxifen also reduced the expression of several known estrogen response genes including GREB1, which is thought to mediate estrogen-induced proliferation (41) , (42), (43) .
Our approach to gene expression analysis imposes certain limitations in interpretation. Analysis of the gene expression microarray data was directed at identifying the most consistent general effects of tamoxifen in benign breast tissue and will have excluded genes with large expression changes in just a few individuals.
Hierarchical clustering, as shown in Figure 2 , was used to confirm that the variability in up or downregulation of the selected genes was greater between treatment groups then within groups. In addition, the stringent statistical criteria used for gene selection will have excluded many important genes with more modest modulation. For example, downregulation of the calcium/calmodulin-dependent protein kinase (CAMK) CAMK2G has previously been reported in tamoxifen-treated premenopausal women (44) . Our data did not confirm this observation, but did show modulation of a variety of other CAMKrelated genes, none of which met our statistical criteria for inclusion in the final lists. Tamoxifen has been associated with reduced proliferation in benign breast epithelial cells in some studies (46) , (47), (48), but not others (49) . The three positive studies are from the same institution and proliferation was only measured at a single posttreatment time point in premenopausal women undergoing fibroadenoma excision. Of note, mean proliferation in the control groups was highly variable for these three studies Mean post-treatment NRQ was compared with baseline NRQ using paired T-tests, *** P < 0.001, ** P < 0.01, and *P < 0.05. 32 tissue core biopsies (C, D, G, and H). ETV4 was not expressed in human testis, but extensive nuclear staining was observed in breast cancer. ETV4 protein expression was primarily confined to the cytoplasm of luminal mammary epithelial cells (C, arrow), but rare epithelial structures with strong nuclear staining were also observed (D, arrow).
ETV5 showed strong nuclear staining in a subpopulation of cells from testis (E), breast cancer (F), and benign breast epithelial structures (G and H). 
